Kartsonis NA - Search Results

1

Caspofungin: the first in a new class of antifungal agents.

Kartsonis NA, Nielsen J, Douglas CM. Kartsonis NA, et al. Drug Resist Updat. 2003 Aug;6(4):197-218. doi: 10.1016/s1368-7646(03)00064-5. Drug Resist Updat. 2003. PMID: 12962685 Review.

2

Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study.

Kartsonis NA, Saah A, Lipka CJ, Taylor A, Sable CA. Kartsonis NA, et al. J Antimicrob Chemother. 2004 May;53(5):878-81. doi: 10.1093/jac/dkh179. Epub 2004 Mar 24. J Antimicrob Chemother. 2004. PMID: 15044431 Clinical Trial.

3

Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome.

Kartsonis N, Killar J, Mixson L, Hoe CM, Sable C, Bartizal K, Motyl M. Kartsonis N, et al. Antimicrob Agents Chemother. 2005 Sep;49(9):3616-23. doi: 10.1128/AAC.49.9.3616-3623.2005. Antimicrob Agents Chemother. 2005. PMID: 16127030 Free PMC article.

4

Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients.

Li CC, Sun P, Dong Y, Bi S, Desai R, Dockendorf MF, Kartsonis NA, Ngai AL, Bradshaw S, Stone JA. Li CC, et al. Among authors: kartsonis na. Antimicrob Agents Chemother. 2011 May;55(5):2098-105. doi: 10.1128/AAC.00905-10. Epub 2011 Feb 7. Antimicrob Agents Chemother. 2011. PMID: 21300834 Free PMC article.

5

Overview of safety experience with caspofungin in clinical trials conducted over the first 15 years: a brief report.

Ngai AL, Bourque MR, Lupinacci RJ, Strohmaier KM, Kartsonis NA. Ngai AL, et al. Among authors: kartsonis na. Int J Antimicrob Agents. 2011 Dec;38(6):540-4. doi: 10.1016/j.ijantimicag.2011.07.008. Epub 2011 Sep 16. Int J Antimicrob Agents. 2011. PMID: 21925846 Review.

6

Efficacy and safety of caspofungin in obese patients.

Ryan DM, Lupinacci RJ, Kartsonis NA. Ryan DM, et al. Among authors: kartsonis na. Med Mycol. 2011 Oct;49(7):748-54. doi: 10.3109/13693786.2011.571293. Med Mycol. 2011. PMID: 21466264

7

Efficacy and safety of caspofungin therapy in elderly patients with proven or suspected invasive fungal infections.

Dinubile MJ, Strohmaier KM, Lupinacci RJ, Meibohm AR, Sable CA, Kartsonis NA. Dinubile MJ, et al. Among authors: kartsonis na. Eur J Clin Microbiol Infect Dis. 2008 Aug;27(8):663-70. doi: 10.1007/s10096-008-0486-6. Epub 2008 Mar 7. Eur J Clin Microbiol Infect Dis. 2008. PMID: 18324427 Clinical Trial.

8

Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole.

Kartsonis N, DiNubile MJ, Bartizal K, Hicks PS, Ryan D, Sable CA. Kartsonis N, et al. J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):183-7. doi: 10.1097/00126334-200210010-00009. J Acquir Immune Defic Syndr. 2002. PMID: 12394797 Clinical Trial.

9

Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study.

Kartsonis NA, Saah AJ, Joy Lipka C, Taylor AF, Sable CA. Kartsonis NA, et al. J Infect. 2005 Apr;50(3):196-205. doi: 10.1016/j.jinf.2004.05.011. J Infect. 2005. PMID: 15780413

10

Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age.

Sáez-Llorens X, Macias M, Maiya P, Pineros J, Jafri HS, Chatterjee A, Ruiz G, Raghavan J, Bradshaw SK, Kartsonis NA, Sun P, Strohmaier KM, Fallon M, Bi S, Stone JA, Chow JW. Sáez-Llorens X, et al. Among authors: kartsonis na. Antimicrob Agents Chemother. 2009 Mar;53(3):869-75. doi: 10.1128/AAC.00868-08. Epub 2008 Dec 15. Antimicrob Agents Chemother. 2009. PMID: 19075070 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

60 results

Search Page